Major orthopedics companies could soon bid adieu to outside monitors who have watched them to ensure above-board financial relationships with surgeons, but the good behavior is expected to continue.
The monitors were appointed in 2007 under agreements the five big orthopedics firms signed with the U.S. government to resolve allegations of improper surgeon payments. While those agreements are set to expire at the end of March, they will end amid a wider push for increased transparency.
Orthopedics firms and other medical companies seem to see the handwriting on the wall. Pharmaceutical giant Pfizer Inc. (PFE) joined on Monday, for example, a list of drug makers that have pledged to disclose various payments to doctors.